Miami Cancer Institute Women’s Cancer Symposium, Third Annual Symposium Evaluation

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence Not applicable|Not applicable

	5	4	3	2	1	Not applicable
Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer.	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - 5	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - 4	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - 3	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - 2	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - 1	Incorporate strategies for the prevention, mitigation and management of treatment-related adverse events for patients undergoing treatment for breast cancer. - Not applicable
Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers.	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - 5	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - 4	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - 3	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - 2	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - 1	Discuss the future of therapeutic strategies in the treatment of gynecologic and breast cancers. - Not applicable
Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes.	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - 5	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - 4	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - 3	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - 2	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - 1	Apply the new standards of care in gynecologic and breast cancers to improve patient outcomes. - Not applicable

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Universal Genetic Testing for Breast Cancer? Mark Robson, M.D.	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - 5	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - 4	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - 3	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - 2	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - 1	Universal Genetic Testing for Breast Cancer? Mark Robson, M.D. - NA
Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D.	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - 5	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - 4	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - 3	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - 2	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - 1	Incorporating IO and Emerging Therapeutic Options for TNBC - Rita Nanda, M.D. - NA
Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D.	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - 5	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - 4	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - 3	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - 2	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - 1	Management of the Ptotic Breast from a Breast Plastic Reconstructive Standpoint - Miguel Medina, M.D. - NA
Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D.	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - 5	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - 4	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - 3	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - 2	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - 1	Future of Robotic Surgery in Gynecologic Oncology - Martin Martino, M.D. - NA
Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - 5	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - 4	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - 3	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - 2	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - 1	Maintenance Therapy in Ovarian Cancer: To PARP or Not To PARP - Robert Coleman, MD - NA
Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - 5	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - 4	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - 3	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - 2	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - 1	Evolution of the Treatment and Research Landscape in Cervical Cancer: A New Hope - Robert Coleman, MD - NA
State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D.	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - 5	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - 4	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - 3	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - 2	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - 1	State of the Art for Ovarian and Endometrial Cancers - Kathleen Moore, M.D. - NA
Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D.	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - 5	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - 4	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - 3	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - 2	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - 1	Innovations in the Surgical Management of Endometrial Cancer - Nadeem Abu-Rustum, M.D. - NA
Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D.	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - 5	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - 4	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - 3	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - 2	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - 1	Role of Immunotherapy in the Management of Endometrial Cancer - Matt Powell, M.D. - NA
Integrative Medicine Approaches - Ashwin Mehta, M.D.	Integrative Medicine Approaches - Ashwin Mehta, M.D. - 5	Integrative Medicine Approaches - Ashwin Mehta, M.D. - 4	Integrative Medicine Approaches - Ashwin Mehta, M.D. - 3	Integrative Medicine Approaches - Ashwin Mehta, M.D. - 2	Integrative Medicine Approaches - Ashwin Mehta, M.D. - 1	Integrative Medicine Approaches - Ashwin Mehta, M.D. - NA
Targeting HER2 - Reshma Mahtani, MD	Targeting HER2 - Reshma Mahtani, MD - 5	Targeting HER2 - Reshma Mahtani, MD - 4	Targeting HER2 - Reshma Mahtani, MD - 3	Targeting HER2 - Reshma Mahtani, MD - 2	Targeting HER2 - Reshma Mahtani, MD - 1	Targeting HER2 - Reshma Mahtani, MD - NA
Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D.	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - 5	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - 4	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - 3	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - 2	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - 1	Using Genomic Assays to Personalize Treatment Planning - Ann O'Dea, M.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

What, if any, new skills/strategies will you apply in your clinical practice? *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

Attestation *

Choose 1 option

I attest that I have participated in this live symposium in its entirety.

I attest that I have participated in _____ hours of instruction (max 6.25) during this live symposium.

hours attestation *

Hours attended

You are here

Miami Cancer Institute Women’s Cancer Symposium, Third Annual Symposium Evaluation